{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:39:30Z","timestamp":1792726770912,"version":"4.5.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007880","name":"Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007880","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020132","name":"Anthos Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010174","name":"University of Colorado","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010174","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jtha.2024.04.003","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T02:09:33Z","timestamp":1713492573000},"page":"2081-2092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation, analysis, and reporting of medication adherence for clinical trials of anticoagulants in children: guidance from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3150-3239","authenticated-orcid":false,"given":"Meghan E.","family":"McGrady","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Ignjatovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil A.","family":"Goldenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Rizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney D.","family":"Thornburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin E.","family":"Todd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Luchtman-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.04.003_bib1","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/bloodadvances.2017013292","article-title":"Increasing rate of pulmonary embolism diagnosed in hospitalized children in the United States from 2001 to 2014","volume":"2","author":"Carpenter","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.04.003_bib2","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1542\/peds.2009-0768","article-title":"Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007","volume":"124","author":"Raffini","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.jtha.2024.04.003_bib3","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jpeds.2011.03.052","article-title":"Pediatric venous and arterial noncerebral thromboembolism in Denmark: a nationwide population-based study","volume":"159","author":"Tuckuviene","year":"2011","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jtha.2024.04.003_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jtha.2022.11.031","article-title":"High rate of recurrent venous thromboembolism in children and adolescents with unprovoked venous thromboembolism","volume":"21","author":"Whitworth","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.04.003_bib5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/asheducation-2018.1.399","article-title":"Management of thrombosis in children and neonates: practical use of anticoagulants in children","volume":"2018","author":"Monagle","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtha.2024.04.003_bib6","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/PCC.0000000000002826","article-title":"A\u00a0new risk assessment model for hospital-acquired venous thromboembolism in critically ill children: a report from the Children's Hospital-Acquired Thrombosis Consortium","volume":"23","author":"Jaffray","year":"2022","journal-title":"Pediatr Crit Care Med"},{"key":"10.1016\/j.jtha.2024.04.003_bib7","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1542\/peds.2011-1635","article-title":"Pediatric self-management: a framework for research, practice, and policy","volume":"129","author":"Modi","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.jtha.2024.04.003_bib8","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","article-title":"A\u00a0new taxonomy for describing and defining adherence to medications","volume":"73","author":"Vrijens","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2024.04.003_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30076","article-title":"Barriers to medication adherence in children, adolescents, and young adults prescribed anticoagulation","volume":"70","author":"Todd","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtha.2024.04.003_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29698","article-title":"A\u00a0systematic review of adherence to anticoagulation regimens in pediatric patients","volume":"69","author":"Todd","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtha.2024.04.003_bib11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.5428\/pcar20130417","article-title":"One-year adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events","volume":"19","author":"Chen","year":"2013","journal-title":"J\u00a0Manag Care Pharm"},{"key":"10.1016\/j.jtha.2024.04.003_bib12","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12872-017-0671-6","article-title":"Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration","volume":"17","author":"Borne","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jtha.2024.04.003_bib13","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/pbc.25145","article-title":"Venous thromboembolism and anticoagulation safety: who is watching the children?","volume":"61","author":"Luchtman-Jones","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtha.2024.04.003_bib14","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1111\/jth.15730","article-title":"Results of an international survey on adherence with anticoagulation in children, adolescents, and young adults: communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis","volume":"20","author":"McGrady","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.04.003_bib15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1124\/mi.11.2.8","article-title":"The secrets of a successful clinical trial: compliance, compliance, and compliance","volume":"11","author":"Czobor","year":"2011","journal-title":"Mol Interv"},{"key":"10.1016\/j.jtha.2024.04.003_bib16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev-pharmtox-011711-113247","article-title":"Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories","volume":"52","author":"Blaschke","year":"2012","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jtha.2024.04.003_bib17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/clpt.2014.59","article-title":"Methods for measuring, enhancing, and accounting for medication adherence in clinical trials","volume":"95","author":"Vrijens","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jtha.2024.04.003_bib18","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/jcph.689","article-title":"Mitigating the effects of nonadherence in clinical trials","volume":"56","author":"Shiovitz","year":"2016","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jtha.2024.04.003_bib19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF00280102","article-title":"Measurement of patient compliance and the interpretation of randomized clinical trials","volume":"41","author":"Vander Stichele","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2024.04.003_bib20","series-title":"Guidance for industry","article-title":"Enichment strategies for clinical trials to support determination of effectiveness of human drugs and biological products","year":"2019"},{"key":"10.1016\/j.jtha.2024.04.003_bib21","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/bcp.14240","article-title":"How the EMERGE guideline on medication adherence can improve the quality of clinical trials","volume":"86","author":"Eliasson","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2024.04.003_bib22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev.pharmtox.37.1.451","article-title":"Medication compliance as a feature in drug development","volume":"37","author":"Kastrissios","year":"1997","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jtha.2024.04.003_bib23","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1093\/eurheartj\/ehy377","article-title":"Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC)","volume":"40","author":"Valgimigli","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2024.04.003_bib24","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.3389\/fphar.2018.01290","article-title":"A\u00a0systematic review of medication adherence thresholds dependent of clinical outcomes","volume":"9","author":"Baumgartner","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jtha.2024.04.003_bib25","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/MAJ.0b013e318068dde8","article-title":"Reporting of adherence to medication in recent randomized controlled trials of 6 chronic diseases: a systematic literature review","volume":"334","author":"Gossec","year":"2007","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jtha.2024.04.003_bib26","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/pds.4334","article-title":"The myths of medication adherence","volume":"26","author":"Gellad","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jtha.2024.04.003_bib27","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/JCP.0000000000000372","article-title":"Medication nonadherence, \u201cprofessional subjects,\u201d and apparent placebo responders: overlapping challenges for medications development","volume":"35","author":"McCann","year":"2015","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.jtha.2024.04.003_bib28","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1186\/s13063-017-2240-9","article-title":"A\u00a0framework for the design, conduct and interpretation of randomised controlled trials in the presence of treatment changes","volume":"18","author":"Dodd","year":"2017","journal-title":"Trials"},{"key":"10.1016\/j.jtha.2024.04.003_bib29","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/sim.2230","article-title":"The effects of non-compliance on intent-to-treat analysis of equivalence trials","volume":"25","author":"Sheng","year":"2006","journal-title":"Stat Med"},{"key":"10.1016\/j.jtha.2024.04.003_bib30","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/M18-0543","article-title":"ESPACOMP Medication Adherence Reporting Guideline (EMERGE)","volume":"169","author":"De Geest","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2024.04.003_bib31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.jtha.2024.04.003_bib32","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1161\/01.HYP.2.6.757","article-title":"Can simple clinical measurements detect patient noncompliance?","volume":"2","author":"Haynes","year":"1980","journal-title":"Hypertension"},{"key":"10.1016\/j.jtha.2024.04.003_bib33","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(75)92192-3","article-title":"Randomised clinical trial of strategies for improving medication compliance in primary hypertension","volume":"1","author":"Sackett","year":"1975","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2024.04.003_bib34","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1185\/03007990903126833","article-title":"Good and poor adherence: optimal cut-point for adherence measures using administrative claims data","volume":"25","author":"Karve","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jtha.2024.04.003_bib35","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3389\/fphar.2018.01540","article-title":"Is there a threshold for medication adherence? lessons learnt from electronic monitoring of drug adherence","volume":"9","author":"Burnier","year":"2019","journal-title":"Front Pharmacol"},{"issue":"Suppl","key":"10.1016\/j.jtha.2024.04.003_bib36","doi-asserted-by":"crossref","first-page":"188S","DOI":"10.1016\/S0197-2456(00)00077-5","article-title":"Measuring adherence to behavioral and medical interventions","volume":"21","author":"Vitolins","year":"2000","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jtha.2024.04.003_bib37","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1177\/17407745221084127","article-title":"The value of adherence information during clinical pharmaceutical trials","volume":"19","author":"Grayek","year":"2022","journal-title":"Clin Trials"},{"key":"10.1016\/j.jtha.2024.04.003_bib38","first-page":"1","article-title":"Eliciting accurate reports of adherence in a clinical interview: development of the Medical Adherence Measure","volume":"34","author":"Zelikovsky","year":"2008","journal-title":"Pediatr Nurs"},{"key":"10.1016\/j.jtha.2024.04.003_bib39","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/jpepsy\/jsz096","article-title":"Patient-reported outcomes for pediatric adherence and self-management: a systematic review","volume":"45","author":"Plevinsky","year":"2020","journal-title":"J\u00a0Pediatr Psychol"},{"key":"10.1016\/j.jtha.2024.04.003_bib40","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1177\/03331024221090206","article-title":"Development of a text message-based headache diary in adolescents and children","volume":"42","author":"Kellier","year":"2022","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jtha.2024.04.003_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28767","article-title":"Daily text message assessments of 6-mercaptopurine adherence and its proximal contexts in adolescents and young adults with leukemia: a pilot study","volume":"68","author":"Psihogios","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtha.2024.04.003_bib42","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1089\/apc.2004.18.527","article-title":"Assessing medication adherence in adolescents with HIV when electronic monitoring is not feasible","volume":"18","author":"Wiener","year":"2004","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.jtha.2024.04.003_bib43","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1399-3046.2010.01391.x","article-title":"The Allocation of Treatment Responsibility scale: a novel tool for assessing patient and caregiver management of pediatric medical treatment regimens","volume":"14","author":"Pai","year":"2010","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jtha.2024.04.003_bib44","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/bcp.12942","article-title":"A\u00a0scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence","volume":"82","author":"El Alili","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2024.04.003_bib45","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2016-07-726893","article-title":"Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children\u2019s Oncology Group study","volume":"129","author":"Landier","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.04.003_bib46","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/clpt.1989.122","article-title":"The natural history of medication compliance in a drug trial: limitations of pill counts","volume":"46","author":"Rudd","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jtha.2024.04.003_bib47","first-page":"1","article-title":"Review of the methods to measure non-adherence with a focus on chemical adherence testing","volume":"5","author":"Osman","year":"2022","journal-title":"Transl Metab Syndr Res"},{"key":"10.1016\/j.jtha.2024.04.003_bib48","first-page":"1073","article-title":"Navigating the wild west of medication adherence reporting in specialty pharmacy","volume":"25","author":"Canfield","year":"2019","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.jtha.2024.04.003_bib49","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/0018578720918550","article-title":"Accurate medication adherence measurement using administrative data for frequently hospitalized patients","volume":"56","author":"Rasu","year":"2021","journal-title":"Hosp Pharm"},{"key":"10.1016\/j.jtha.2024.04.003_bib50","doi-asserted-by":"crossref","first-page":"419","DOI":"10.7326\/M17-3306","article-title":"An independent evaluation of the accuracy and usability of electronic adherence monitoring devices","volume":"169","author":"McGrady","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2024.04.003_bib51","first-page":"27","article-title":"Anticoagulant therapy in pediatrics","volume":"5","author":"Dabbous","year":"2014","journal-title":"J\u00a0Basic Clin Pharm"},{"key":"10.1016\/j.jtha.2024.04.003_bib52","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bcmd.2017.05.008","article-title":"Anticoagulation therapy in neonates, children and adolescents","volume":"67","author":"Hepponstall","year":"2017","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.jtha.2024.04.003_bib53","first-page":"7926","article-title":"Warfarin adherence and anticoagulation control in atrial fibrillation patients: a systematic review","volume":"25","author":"Ababneh","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jtha.2024.04.003_bib54","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/10998004221127977","article-title":"Determination of factors affecting time in therapeutic range in patients on warfarin therapy","volume":"25","author":"Turen","year":"2023","journal-title":"Bio Res Nurs"},{"key":"10.1016\/j.jtha.2024.04.003_bib55","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1097\/MPH.0000000000001769","article-title":"Participant-reported warfarin adherence in community-based pediatric patients","volume":"42","author":"Zhao","year":"2020","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.jtha.2024.04.003_bib56","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/MPH.0000000000000502","article-title":"Safety and efficacy outcomes of home and hospital warfarin management within a pediatric anticoagulation clinic","volume":"38","author":"Jones","year":"2016","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.jtha.2024.04.003_bib57","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.thromres.2008.07.012","article-title":"KIDCLOT: the importance of validated educational intervention for optimal long term warfarin management in children","volume":"123","author":"Bauman","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.04.003_bib58","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.thromres.2013.04.028","article-title":"The economic costs of routine INR monitoring in infants and children--examining point-of-care devices used within the home setting compared to traditional anticoagulation clinic monitoring","volume":"132","author":"Gaw","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.04.003_bib59","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1001\/jama.2022.21022","article-title":"Guidelines for reporting outcomes in trial reports: the CONSORT-Outcomes 2022 extension","volume":"328","author":"Butcher","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2024.04.003_bib60","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jclinepi.2018.12.002","article-title":"An overview of statistical methods for handling nonadherence to intervention protocol in randomized control trials: a methodological review","volume":"108","author":"Mostazir","year":"2019","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jtha.2024.04.003_bib63","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1097\/CCM.0000000000004784","volume":"49","author":"Faustino","year":"2021","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jtha.2024.04.003_bib64","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jama.2021.23182","article-title":"Effect of anticoagulant therapy for 6 weeks vs 3 months on recurrence and bleeding events in patients younger than 21 years of age with provoked venous thromboembolism: the Kids-DOTT randomized clinical trial","volume":"327","author":"Goldenberg","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2024.04.003_bib65","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3324\/haematol.2018.194175","article-title":"THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents","volume":"104","author":"Greiner","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.04.003_bib66","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/S2352-3026(20)30368-9","article-title":"Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b\/3, non-inferiority trial","volume":"8","author":"Halton","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2024.04.003_bib67","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29764","article-title":"A\u00a0phase 2 pharmacodynamic dose-finding, safety, and efficacy study of dalteparin for pediatric venous thromboembolism treatment in children with and without cancer","volume":"69","author":"Hartman","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtha.2024.04.003_bib68","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12959-018-0188-y","article-title":"Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study","volume":"16","author":"Lensing","year":"2018","journal-title":"Thromb J"},{"key":"10.1016\/j.jtha.2024.04.003_bib69","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S2352-3026(19)30219-4","article-title":"Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial","volume":"7","author":"Male","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2024.04.003_bib70","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jacc.2012.08.1023","article-title":"Factors associated with thrombotic complications after the Fontan procedure: a secondary analysis of a multicenter, randomized trial of primary thromboprophylaxis for 2 years after the Fontan procedure","volume":"61","author":"McCrindle","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2024.04.003_bib71","article-title":"Thromboprophylaxis for children post-Fontan procedure: insights from the UNIVERSE study","volume":"10","author":"McCrindle","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jtha.2024.04.003_bib72","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ahj.2019.04.009","article-title":"Rivaroxaban, a direct factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: rationale and design of a prospective, randomized trial (the UNIVERSE study)","volume":"213","author":"Pina","year":"2019","journal-title":"Am Heart J"},{"key":"10.1016\/j.jtha.2024.04.003_bib73","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1055\/s-0039-1679938","article-title":"PREVAPIX-ALL: apixaban compared to standard of care for prevention of venous thrombosis in paediatric acute lymphoblastic leukaemia (ALL)-rationale and design","volume":"119","author":"O'Brien","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.04.003_bib74","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ahj.2019.08.002","article-title":"A\u00a0multi-national trial of a direct oral anticoagulant in children with cardiac disease: design and rationale of the Safety of Apixaban on Pediatric Heart Disease on the Prevention of Embolism (SAXOPHONE) study","volume":"217","author":"Payne","year":"2019","journal-title":"Am Heart J"},{"key":"10.1016\/j.jtha.2024.04.003_bib75","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.jacc.2022.09.031","article-title":"Edoxaban for thromboembolism prevention in pediatric patients with cardiac disease","volume":"80","author":"Portman","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624002174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624002174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T12:02:44Z","timestamp":1751371364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624002174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":73,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1538783624002174"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.04.003","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation, analysis, and reporting of medication adherence for clinical trials of anticoagulants in children: guidance from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}